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Abstract A recombinant vaccinia virus expressing canine
interferon (IFN)-L was constructed (vv/cIFN-L). In rabbit kidney
(RK13) and canine A72 cells infected with vv/cIFN-L, the
recombinant canine IFN-L was detected in both cell extracts and
supernatants, and the IFN activities of the culture supernatants
were also detected. Inhibition of N-linked glycosylation by
tunicamycin treatment indicated that the recombinant canine
IFN-L was modified by N-linked glycosylation in a different way
between RK13 and A72 cells, and that N-linked glycosylation is
essential for its secretion. The growth of vv/cIFN-L at a low
multiplicity of infection was inhibited by antiviral activity of
canine IFN-L, indicating that this recombinant virus could be
used as a suicide viral vector.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
Interferons (IFNs) are characterized primarily by their anti-
viral activity [1]. Due to their multifunctional nature, such as
anti-proliferative and immunomodulatory e¡ects, IFNs have
been used in clinical application against a number of diseases
[2]. The IFNs are divided into types I and II. IFN-K, -L, -d
and -g are members of type I IFN, whereas IFN-Q is that of
type II IFN.
Vaccinia virus belongs to the family poxviridae and is the
most intensively studied member among the poxvirus family
[3]. The poxviruses replicate in the cytoplasm of infected cells
without nuclear enzymes of the host cells for their transcrip-
tion or DNA synthesis. Vaccinia virus has circumvented this
problem by encoding or packaging a complete enzyme system
necessary for transcription [4] and DNA synthesis, including a
DNA-dependent DNA polymerase [5^8], DNA topoisomerase
[9], DNA ligase [10^12], and nicking^joining enzyme [13,14].
The vaccinia virus has been widely used as an expression
system in molecular biology. Although some studies about
recombinant vaccinia virus producing IFN-Q were reported
[15^17], vaccinia virus has not been used in expression of
IFN-L yet. Vaccinia virus might have unique properties which
are di¡erent from those of other viral vectors, since vaccinia
virus encodes anti-IFN genes [18,19]. In this study, we con-
struct a recombinant vaccinia virus which expresses canine
IFN-L, and characterize the production of canine IFN-L
and the replication of the recombinant virus.
2. Materials and methods
2.1. Cells and viruses
Rabbit kidney (RK13) cells were cultured in Eagle’s minimum es-
sential medium (EMEM, Nissui) supplemented with 7.5% heat-inacti-
vated fetal bovine serum (FBS). Canine A72 cells (ATCC no. CCL-
34) were cultured in L15 medium (Gibco Lab.) supplemented with
20% heat-inactivated FBS. Vaccinia virus LC16mO (mO) strain and
its recombinant were propagated in RK13 cells in EMEM supple-
mented with 7.5% FBS.
2.2. Construction of recombinant vaccinia virus which expresses canine
IFN-L
The open reading frame of the canine IFN-L was ampli¢ed by
polymerase chain reaction (PCR) using a pair of primers, 5P-CCGA-
ATTCATCGAGATGGTAATAGGTGA-3P (5-IFNb) and 5P-CAGT-
CGACTCAGTTCTGGAGATAATCTG-3P (3-IFNb), and pCaIB31V
as template [20]. The PCR products were blunted by Klenow fragment
and ligated with the vaccinia virus transfer vector pAK8 [21], which
was cut with Sal and Bgl and then blunted. The plasmid (pAK/cIFN-
L), which has the right orientation of the insert to promoter, was
transfected to RK13 cells by Lipofectin1 reagent (Gibco BRL) 2 h
after infection with the mO strain. After 2 days cultivation, culture
medium was collected. To isolate recombinant viruses arisen from
homologous recombination between pAK8 and viral thymidine kinase
(TK) gene, the sample was infected to 143 TK negative (TK3) cells in
the presence of 100 Wg/ml 5-bromo-2P-deoxyuridine, to select TK3
viruses by plaque isolation.
2.3. Sodium dodecyl sulfate^polyacrylamide gel electrophoresis
(SDS^PAGE) and Western blot analysis
RK13 cells and A72 cells in a 35 mm diameter tissue culture dish
were infected with the mO strain or the recombinant vaccinia virus at
a multiplicity of infection (moi) of 5 for 2 h at 37‡C. Then, the cells
were washed with phosphate-bu¡ered saline (PBS) and cultured in
500 Wl of the medium at 37‡C for 48 h. At the end of the culture,
the culture medium was harvested from the infected cells, and then
vaccinia virions were removed from the medium by centrifugation at
35 000 rpm for 120 min in a Beckman SW41Ti rotor. The cell extracts
were prepared by sonication in 500 Wl of PBS. The samples were
subjected to SDS^PAGE under reducing conditions, and then pro-
teins were electrically transferred to a membrane (Immobilon Transfer
Membranes, Millipore). The membrane was immersed in blocking
bu¡er (PBS containing 3% skim milk) at 37‡C for 60 min, incubated
with a rabbit anti-canine IFN-L serum diluted in the blocking bu¡er
at 37‡C for 60 min, and then incubated with horseradish peroxidase-
conjugated goat anti-rabbit (IgG and IgM) antibodies diluted in the
blocking bu¡er at 37‡C for 60 min after washing three times with
PBS. The membrane was reacted with enhanced chemo-luminescence
(ECL) detection reagents (Amersham) for 1 min, and was then ex-
posed to a ¢lm (Kodak Scienti¢c Imaging Film, Kodak) after washing
three times with PBS.
2.4. Rabbit antiserum against canine IFN-L
Canine IFN-L, expressed in Escherichia coli under the control of trc
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promoter (pSE3801, Invitrogen Corporation), formed inclusion
bodies. Thus the IFN-L protein was puri¢ed by washing with 6 M
guanidine^HCl three times and by separation in SDS^PAGE. The gel
slices containing canine IFN-L protein were immunized to JW-NIBS
rabbits (Nisseiken) with Freund’s complete adjuvant four times at
intervals of 2 weeks. The hyperimmune serum gave a positive signal
at 106 dilution in Western blot using 1 ng of canine IFN-L.
2.5. Assay of IFN activity
The antiviral activity of canine IFN-L was assayed by its ability to
inhibit cytopathic e¡ects of vesicular stomatitis virus grown in A72
cells in 96 well tissue culture plates, and was shown as a laboratory
unit (LU) [22]. The supernatants were centrifuged as in Section 2.3 to
remove vaccinia virion and checked the absence of infectious virus
before IFN assay.
3. Results
3.1. Expression of canine IFN-L by recombinant vaccinia virus
in RK13 cells
The recombinant vaccinia virus, vv/cIFN-L, which expresses
canine IFN-L under a promoter of P7:5, was infected to RK13
cells at a moi 5. After 48 h, cell extracts and supernatants
were prepared and analyzed by a Western blotting method
using an anti-canine IFN-L serum (Fig. 1). Several sizes of
canine IFN-L were secreted in supernatants, as we detected
a broad band of 39^27 kDa (Fig. 1, lane 1). The IFN activity
of the culture supernatant was 5.3U104 LU/ml. On the other
hand, smaller sizes (30^23 kDa) of canine IFN-L were de-
tected in the cell extracts (Fig. 1, lane 3). Apparent molecular
weights of these canine IFN-L molecules were greater than
those predicted from the canine IFN-L gene sequence (20
kDa) [20]. To test whether the increase of molecular weight
in canine IFN-L was due to glycosylation, the infected cells
were treated with tunicamycin (TM). As a result, no protein
was secreted in the supernatant from infected cells treated
with TM (Fig. 1, lane 2). In the cell extracts, the apparent
molecular weights of canine IFN-L were reduced to 24 and
21^18 kDa (Fig. 1, lane 4), indicating that the secreted canine
IFN-L was modi¢ed by N-linked sugars. Among them, the 24
kDa and 18 kDa molecules would be a proprotein (predicted
molecular weight is 23 kDa) and a matured but non-glycosy-
lated one (predicted molecular weight is 20 kDa), respectively.
Thus, canine IFN-L was mostly modi¢ed by N-linked sugars.
3.2. Time course of canine IFN-L production in the vaccinia
virus system
To analyze the kinetics of expression of canine IFN-L gene
product, cell extracts and supernatants from RK13 cells in-
fected with vv/cIFN-L were collected from 12 to 72 h post
infection (pi) (Fig. 2). The canine IFN-L was ¢rst detectable
at 24 h pi in the cell extract and the supernatant (Fig. 2A,C).
The amount of canine IFN-L increased from 24 to 36 h pi,
and reached plateau levels by 72 h pi (Fig. 2A,C). In the
infected RK13 cell extracts treated with TM, the canine
IFN-L was ¢rst detectable at 12 h pi (Fig. 2B). At the time,
only 23 kDa of proprotein and 18 kDa mature protein were
detected. Subsequently, 21 kDa and 19 kDa proteins were
detected 24 h pi. No canine IFN-L was detected in the super-
natants treated with TM, throughout the cultivation period
(data not shown).
3.3. Expression of canine IFN-L by recombinant vaccinia virus
in canine cells
To test the possibility whether infection of vv/cIFN-L pro-
duces canine IFN-L, which, in turn, induces the antiviral state
in canine cells, a canine A72 cell line was infected with vv/
cIFN-L at 5 plaque forming units (PFU)/cell and production
of canine IFN-L was analyzed by Western blot (Fig. 3). The
IFN activity of the culture supernatant was 5U103 LU/ml,
about one tenth of that in RK13 cells. As shown in Fig. 3,
34 and 29 kDa proteins were detected in the supernatant and
33, 28 and 25 kDa proteins were detected in cell extracts (Fig.
3, lanes 1 and 3). No protein was detected in the supernatant
from the infected cells treated with TM (Fig. 3, lane 4), but in
cell extract, smaller molecules of 24, 21 and 19 kDa were
detected as in RK13 cells (Fig. 3, lane 2). The di¡erence in
molecular weight of the secreted canine IFN-L between A72
and RK13 cells may re£ect the di¡erent glycosylation between
the two cell lines.
Fig. 1. Western blot analysis of canine IFN-L in RK13 cells. Super-
natants (lanes 1 and 2) and extracts (lanes 3 and 4) of RK13 cells
infected with recombinant vaccinia virus were analyzed using anti-
canine IFN-L serum. Supernatants (lane 2) and extracts (lane 4) of
infected RK13 cells were treated with TM. Molecular weights of
markers are given in kDa.
Fig. 2. Kinetics of canine IFN-L synthesis. RK13 cells were infected with recombinant vaccinia virus and harvested at 12 (lane 1), 24 (lane 2),
36 (lane 3), 48 (lane 4), 60 (lane 5) and 72 h pi (lane 6). Extracts (A) and supernatants (C) of infected RK13 cells were analyzed by Western
blot. B shows that extracts of infected RK13 cells were treated with TM. Molecular weights of markers are given in kDa.
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3.4. Growth analysis of vv/cIFN-L in RK13 cells and A72 cells
Next, we determined the e¡ect of expression of canine IFN-
L on the growth of the recombinant virus in A72 and RK13
cells. Single- and multi-step growth curves of mO and vv/
cIFN-L were compared (Fig. 4). At 5 PFU/cell (single-step
growth), both mO and vv/cIFN-L grew with peak titers of
2U106 PFU/ml in A72 cells (Fig. 4A). However, at 0.01
PFU/ml (multi-step growth), no vv/cIFN-L grew in A72 cells,
whereas the mO grew with a peak titer of 3.6U105 PFU/ml
(Fig. 4B). On the other hand, the vv/cIFN-L grew in RK13
cells with peak titers of 5.5U107 PFU/ml (multi-step growth)
(Fig. 4C) and 2.2U108 PFU/ml (single-step growth) (Fig. 4D),
as in the case of mO. Therefore, the expressed canine IFN-L
could inhibit the growth of recombinant virus in canine cells
only in infection at a low moi.
4. Discussion
The expression of IFN-L has been performed by using sev-
eral expression systems [20,23,24]. However, expression of
IFN-L by using vaccinia virus has not been reported. There
is a possibility that the property of vaccinia virus, which en-
codes anti-IFN genes [18,19], is di¡erent from those of other
systems. In this study, recombinant vaccinia virus, which ex-
presses canine IFN-L, was constructed (vv/cIFN-L). The se-
creted canine IFN-L had the apparent molecular weights of
39^27 kDa and was greater than that of canine IFN-L found
in RK13 cells (30^23 kDa). When the infected cells were
treated with TM, apparent molecular weights of canine
IFN-L in the cells were 24 and 21^18 kDa (four proteins),
suggesting that canine IFN-L was modi¢ed by several N-
linked glycosylations. Among these four molecules, 18 kDa
molecule is the mature protein without glycosylation because
the same size of molecules was detected in recombinant E. coli
which expressed canine IFN-L (data not shown). The 24 kDa
molecule seems to be a proprotein, because the molecular
weight of canine IFN-L with signal sequence is 24 kDa calcu-
Fig. 3. Western blot analysis of canine IFN-L in A72 cells. Extracts
(lanes 1 and 2) and supernatants (lanes 3 and 4) of A72 cells in-
fected with recombinant vaccinia virus were analyzed using anti-ca-
nine IFN-L serum. Supernatants (lane 4) and extracts (lane 2) of in-
fected RK13 cells were treated with TM. Molecular weights of
markers are given in kDa.
Fig. 4. Single-step and multi-step growth analyses. A72 cells were infected with mO or vv/cIFN-L at 5 PFU/cell (A) or 0.01 PFU/cell (B). RK13
cells were infected with mO or recombinant vaccinia virus at 5 PFU/cell (C) or 0.01 PFU/cell (D). Samples were harvested at the indicated
time points and progeny virus was titered on RK13 cells in duplicate. (E) = mO; (7) = vv/cIFN-L.
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lated from amino acid sequence. These two molecules were
observed at 12 h pi. Shortly after, two proteins of molecular
weights 21 and 19 kDa appeared. These molecules seem to be
artifacts by treatment of TM or to be molecules with another
glycosylation, such as O-linked glycosylation. In addition, TM
treatment completely abolished secretion of canine IFN-L,
indicating that N-linked glycosylation is essential for canine
IFN-L secretion.
In canine A72 cells, the canine IFN-L was also modi¢ed by
several N-linked glycosylations which was essential for its
secretion. Judged from the molecular weights of secreted ca-
nine IFN-L, glycosylation was di¡erent between RK13 cells
and canine A72 cells. Furthermore, N-linked glycosylation of
recombinant canine IFN-L in baculovirus expression system
was di¡erent from those of protein expressed by recombinant
vaccinia virus (personal communication). Detail analysis of
human IFN-Q demonstrated that carbohydrate moieties were
di¡erent among animal expression systems [25].
The IFN activity of the culture supernatant of the vv/cIFN-
L-infected cells was demonstrated, but was not e¡ective to
inhibit the vector’s growth in RK13 cells, as expected from
species speci¢city of IFN-L. On the other hand, in canine A72
cells, vv/cIFN-L did not grow at a low moi though both mO
and vv/cIFN-L grew at a high moi. Vaccinia virus is resistant
against IFN action since it encodes four anti-IFN genes:
K3L; molecular decoy of eukaryotic initiation factor 2 K
chain, which is one of the targets of IFN-induced dsRNA-
dependent protein kinase (PKR) [18], E3L; binding to
dsRNA to inhibit PKR competitively [18], B18R and B8R;
receptor homologues of type I and type II IFN, respectively
[19]. However, in infection at a low moi of the vv/cIFN-L,
large amounts of IFN-L expressed at the site of viral growth
inhibited spread of the virus by a strongly induced antiviral
activity of the canine IFN-L.
Recently, gene therapies using viral vector containing the
IFN gene were developed, mainly expecting IFN’s immune
modulatory and anti-tumor activities [26^31], and among
them, some were at phase I trial [26,29]. Our results suggested
that introduction of the IFN gene into vaccinia virus vector
reduced viral replication and cytotoxicity in vitro. By ¢ne
tuning of activities of IFN-L and anti-IFN genes, virulence
of vaccinia virus vector could be controlled for application
in vivo.
Acknowledgements: This work was supported by the grants from the
Ministry of Education, Science, Sports and Culture of Japan. The ¢rst
author is supported by research fellowships of the Japan society for
the promotion of science for young scientists.
References
[1] Gutterman, J.U. (1994) Proc. Natl. Acad. Sci. USA 91, 1198^
1205.
[2] DeMaeyer, E., Galasso, G. and Schellekens, H. (1981) The Biol-
igy of the Interferon System, Elsevier/North-Holland Biomedical,
Amsterdam.
[3] Moss, B. (1990) in: Virology (Field, B.N., Ed.), 2nd edn., pp.
2079^2133, Raven Press, New York.
[4] Moss, B. (1990) Annu. Rev. Biochem. 59, 661^688.
[5] Moss, B. and Cooper, N. (1982) J. Virol. 43, 673^678.
[6] Jones, E.V. and Moss, B. (1984) J. Virol. 49, 72^77.
[7] Traktman, P., Sridhar, P., Condit, R.C. and Roberts, B.E. (1984)
J. Virol. 49, 125^131.
[8] Earl, P.L., Jones, E.V. and Moss, B. (1986) Proc. Natl. Acad. Sci.
USA 83, 3659^3663.
[9] Shuman, S. and Moss, B. (1987) Proc. Natl. Acad. Sci. USA 84,
7478^7482.
[10] Smith, G.L., Chan, Y.S. and Kerr, S.M. (1989) Nucleic Acids
Res. 17, 7581^7590.
[11] Kerr, S.M. and Smith, G.L. (1989) Nucleic Acids Res. 17, 9039^
9050.
[12] Colinas, J.R., Goebel, S.J., Davis, S.W., Johnson, G., Norton,
E.K. and Paoletti, E. (1990) Virology 197, 267^275.
[13] Lakritz, N., Foglesong, P.D., Reddy, M., Baum, S., Hurwitz, J.
and Bauer, W.R. (1985) J. Virol. 53, 935^943.
[14] Reddy, M.K. and Bauer, W.R. (1989) J. Biol. Chem. 264, 443^
449.
[15] Kohonen-Corish, M.R., Blanden, R.V. and King, N.J. (1989)
J. Immunol. 143, 623^627.
[16] Kohonen-Corish, M.R., King, N.J., Woodhams, C.E. and Ram-
shaw, I.A. (1990) Eur. J. Immunol. 20, 157^161.
[17] Peplinski, G.R., Tsung, K., Meko, J.B. and Norton, J.A. (1996)
Ann. Surg. Oncol. 3, 15^23.
[18] Davies, M.V., Chang, H.-W., Jacobs, B.L. and Kaufman, R.J.
(1993) J. Virol. 67, 1688^1692.
[19] Symons, J.A., Alcami, A. and Smith, G.L. (1995) Cell 81, 551^
560.
[20] Iwata, A., Saito, T., Iwata, M.N., Fujino, M., Katsumata, A.,
Hamada, K., Sokawa, Y. and Ueda, S. (1996) J. Interferon Cy-
tokine Res. 16, 765^770.
[21] Yasuda, A., Kimura-Kuroda, J., Ogimoto, M., Miyamoto, M.,
Sata, T., Sato, T., Takamura, C., Kurata, T., Kojima, A. and
Yasui, K. (1990) J. Virol. 64, 2788^2795.
[22] Iwata, A., Iwata, M.N., Saito, T., Hamada, K., Sokawa, Y. and
Ueda, S. (1996) J. Vet. Med. Sci. 58, 23^27.
[23] Leung, D.W., Capon, D.J. and Goeddel, D.V. (1984) Bio/tech-
nology 2, 458^464.
[24] Himmler, A., Hauptmann, R., Adolf, G.R. and Swetly, P. (1986)
DNA 5, 345^356.
[25] James, D.C., Freedman, R.B., Hoare, M., Ogonah, O.W., Roo-
ney, B.C., Larionov, O.A., Dobrovolsky, V.N., Lagutin, O.V.
and Jenkins, N. (1995) Biotechnology 13, 592^596.
[26] Nemunaitis, J., Fong, T., Burrows, F., Bruce, J., Peters, G.,
Ognoskie, N., Meyer, W., Wynne, D., Kerr, R., Pippen, J., Old-
ham, F. and Ando, D. (1999) Hum. Gene Ther. 10, 1289^1298.
[27] Kannno, H., Hattori, S., Sato, H., Murata, H., Huang, F.H.,
Hayashi, A., Suzuki, N., Yamamoto, I., Kawamoto, S., Minami,
M., Miyatake, S., Shuin, T. and Kaplitt, M.G. (1999) Cancer
Gene Ther. 6, 147^154.
[28] Matheux, F., Le Grand, R., Rousseau, V., De Maeyer, E., Dor-
mont, D. and Lauret, E. (1999) Hum. Gene Ther. 10, 429^
440.
[29] Nemunaitis, J., Bohart, C., Fong, T., Meyer, W., Edelman, G.,
Paulson, R.S., Orr, D., Jain, V., O’Brien, J., Kuhn, J., Kowal,
K.J., Burkeholder, S., Bruce, J., Ognoskie, N., Wynne, D., Mar-
tineau, D. and Ando, D. (1998) Cancer Gene Ther. 5, 292^
300.
[30] Stephan, D., San, H., Yang, Z.Y., Gordon, D., Goelz, S., Nabel,
G.J. and Nabel, E.G. (1997) Mol. Med. 3, 593^599.
[31] Mester, J.C., Pitha, P.M. and Glorioso, J.C. (1995) Gene Ther. 2,
187^196.
FEBS 23209 14-1-00
Y. Nishikawa et al./FEBS Letters 466 (2000) 179^182182
